Short answer
Oruka Therapeutics, Inc. (ORKA) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$32M
- −51.5% YoY
Source: XBRL data from the Oruka Therapeutics, Inc. (ORKA) Q1 2026 10-Q on SEC EDGAR. USD.
Oruka Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added Phase 2 ORKA-002 psoriasis trial risk, triggered by dosing commencement in February 2026
- ORKA-001 and ORKA-002 concentration risk, with Phase 2b ORKA-001 dosing begun in fourth quarter 2025
- Regulatory device risk, single-source delivery-device suppliers could delay approval or patient availability
- Enrollment competition risk, increasing approved products and rival trials could delay I&I study timelines
- Equity dilution risk, April 2026 offering raised $700.4 million through 9,660,000 shares
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oruka Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.